Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Paediatric renal tumours: perspectives from the SIOP–RTSG

Nature Reviews Urology volume 14, pages 3–4 (2017)Cite this article

Subjects

Abstract

The >90% rates of overall survival for children with Wilms tumour are remarkable and have been achieved at the same time as reducing treatment for most patients. However, beneath this headline figure, 20% of patients still relapse after first-line therapy and up to 25% of survivors report severe late effects. The aim of the SIOP–RTSG is to improve outcomes and to reduce acute and late treatment toxic effects in all children.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pritchard-Jones, K. et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet 386, 1156–1164 (2015).

    Article  CAS  PubMed  Google Scholar 

  2. de Kraker, J. et al. Wilm's tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. J. Clin. Oncol. 8, 1187–1190 (1990).

    Article  CAS  PubMed  Google Scholar 

  3. Gatta, G. et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5 — a population-based study. Lancet Oncol. 15, 35–47 (2014).

    Article  PubMed  Google Scholar 

  4. Chagtai, T. et al. Gain of 1q as a prognosticbiomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: a SIOP renal tumours biology consortium study. J. Clin. Oncol. 34, 3195–3203 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gratias, E. J. et al. Association of chromosome 1q gain with inferior survival in favorable-histology wilms tumor: a report from the Children's Oncology Group. J. Clin. Oncol. 34, 3189–3194 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Spreafico, F. et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev. Anticancer Ther. 9, 1807–1815 (2009).

    Article  PubMed  Google Scholar 

  7. Graf, N. et al. Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? Pediatr. Blood Cancer 57, 741–742 (2011).

    Google Scholar 

  8. Wegert, J. et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, 298–311 (2015).

    Article  CAS  PubMed  Google Scholar 

  9. Walz, A. L. et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27, 286–297 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hales, P. W., Olsen, Ø. E., Sebire, N. J., Pritchard-Jones, K. & Clark, C. A. A multi-Gaussian model for apparent diffusion coefficient histogram analysis of Wilms' tumour subtype and response to chemotherapy. NMR Biomed. 28, 948–957 (2015).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Filippo Spreafico

Consortia

The SIOP Renal Tumour Study Group

  • Filippo Spreafico
  • , Marry M. van den Heuvel-Eibrink
  • , Kathy Pritchard-Jones
  • , Christophe Bergeron
  • , Jan Godzinski
  • , Anne Smets
  • , Oystein Olsen
  • , Gordan Vujanic
  • , Christian Rübe
  • , Harm van Tinteren
  • , Manfred Gessler
  •  & Norbert Graf

Corresponding author

Correspondence to Filippo Spreafico.

Ethics declarations

Competing interests

The author declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

p-medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

The SIOP Renal Tumour Study Group. Paediatric renal tumours: perspectives from the SIOP–RTSG. Nat Rev Urol 14, 3–4 (2017). https://doi.org/10.1038/nrurol.2016.247

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.247

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer